Nearly 40% of Men Develop New Metabolic Syndrome Within a Year of Starting ARPI Therapy for Prostate Cancer

Why This Study Matters

Androgen receptor pathway inhibitors (ARPIs) — enzalutamide, abiraterone, apalutamide, and darolutamide — given alongside androgen deprivation therapy (ADT), are now standard of care for advanced prostate cancer, a disease that affects roughly 1 in 8 US men over a lifetime, with an estimated 333,830 new cases and 36,320 deaths projected in 2026 by the American Cancer Society.

ADT alone is already known to raise cardiometabolic risk: a pooled analysis of nine prior observational studies found a 75% relative increase in metabolic syndrome risk with ADT (RR 1.75, 95% CI 1.27–2.41), and a 36% increase in diabetes risk (RR 1.36, 95% CI 1.17–1.58). What has been less clear is how quickly metabolic dysfunction emerges once a modern ARPI is layered on top of ADT, and whether that risk varies meaningfully by age — the gap this retrospective cohort study set out to address.

Study Design

This is a retrospective cohort study, not a randomized interventional trial, built on Epic Cosmos — a national, deidentified U.S. electronic health record dataset. Investigators followed adult men with prostate cancer treated between January 2014 and September 2025 for up to 12 months after they began concurrent ADT and an ARPI, with data analysis conducted between October 2025 and January 2026. Because there is no comparator arm, the study describes the trajectory of metabolic risk within this treated population rather than testing an intervention against a control.

Key Findings

Patient Population

Eligible patients had prostate cancer and initiated concurrent ADT–ARPI therapy with no evidence of metabolic syndrome or its individual components before treatment. The cohort of 16,924 men (mean age 73.1 years, SD 9.1) was racially and ethnically diverse: 65.5% non-Hispanic White (11,083), 21.0% non-Hispanic Black (3,562), 5.4% Hispanic (912), and 3.0% Asian (509) individuals. Medical ADT use predominated over surgical castration, and enzalutamide was the most frequently used ARPI in the cohort. The number of contributing study sites was not specified in the source.

Primary Endpoint Results

The primary outcome was new-onset metabolic syndrome within 12 months of starting concurrent ADT–ARPI therapy. Cumulative incidence rose steadily across the follow-up year, approaching 40% by the end of the first year — a rate the study authors describe as frequently documented shortly after treatment initiation.

Subgroup Analyses

Per the source abstract, only the age 70–79 stratum was reported with an exact incidence rate and confidence interval. Other subgroup comparisons were described qualitatively, without specific figures, and are reported here as such rather than as invented numbers.

Metabolic Component Breakdown

This study characterizes cardiometabolic dysfunction rather than the treatment-related adverse events typically reported in a randomized trial. Hypertension was the most frequently documented individual metabolic component among new-onset metabolic syndrome cases. The source abstract does not provide a full breakdown of incidence rates for every individual metabolic component (dyslipidemia, obesity, insulin resistance) or adverse-event rates broken out by specific ARPI agent.

This study found that while ARPIs are standard of care for advanced prostate cancer, metabolic abnormalities were frequently documented shortly after initiation of concurrent ADT and ARPI therapy.
— Study authors, Conclusions and Relevance, JAMA Oncology abstract (verbatim)

Interpretation and Broader Context

Because ARPIs are now standard of care for advanced prostate cancer, these findings suggest oncology teams should extend monitoring beyond cancer-specific outcomes to include early, systematic screening for metabolic dysfunction — ideally through multidisciplinary care involving cardiology or endocrinology — particularly during the first year of ADT–ARPI therapy and especially among patients aged 70–79, who showed the highest observed incidence in this cohort. The study authors call for evaluation of scalable interventions to address cardiometabolic risk in this population, and note that the observed heterogeneity by ARPI type warrants further study into whether specific agents carry differential metabolic risk.

An invited editorial comment accompanying this article, "Managing Metabolic Syndrome and Prostate Cancer" (Marshall and Saad), was published alongside it in the same issue of JAMA Oncology, though its specific content is outside the scope of the source abstract reviewed for this piece.

Limitations

This is a retrospective, single-arm cohort study drawn from real-world electronic health record data, not a randomized trial, so it cannot establish that ARPIs cause metabolic syndrome beyond the risk already attributable to concurrent ADT — it can only describe the rate at which metabolic dysfunction was documented after treatment began. The source available for this article is a published abstract; the full-text manuscript is embargoed until August 13, 2027, so methodological details such as the exact metabolic syndrome case definition, the number of contributing health systems, and complete per-component and per-drug results could not be reviewed. Exact incidence figures were reported for only one age subgroup (70–79 years); other age strata and the ARPI-by-ARPI comparison were described only qualitatively, without confidence intervals, and should be read as exploratory rather than confirmatory. Because the analysis relies on EHR-coded diagnoses, undercoding or inconsistent documentation of metabolic syndrome components across contributing health systems could bias incidence estimates in either direction. Funding and sponsorship were not specified in the source.

Funding & Trial Registration

Trial registration: Not applicable — this is a retrospective real-world data cohort study (Epic Cosmos), not a registered ClinicalTrials.gov interventional trial. Funding/Sponsor: Not specified in source; the accompanying press release does not identify a funding source beyond institutional affiliation (Sidney Kimmel Comprehensive Cancer Center at Jefferson).